James, Nicholas D
Sydes, Matthew R
Clarke, Noel W
Mason, Malcolm D
Dearnaley, David P
Spears, Melissa R
Ritchie, Alastair W S
Parker, Christopher C
Russell, J Martin
Attard, Gerhardt
de Bono, Johann
Cross, William
Jones, Rob J
Thalmann, George
Amos, Claire
Matheson, David
Millman, Robin
Alzouebi, Mymoona
Beesley, Sharon
Birtle, Alison J
Brock, Susannah
Cathomas, Richard
Chakraborti, Prabir
Chowdhury, Simon
Cook, Audrey
Elliott, Tony
Gale, Joanna
Gibbs, Stephanie
Graham, John D
Hetherington, John
Hughes, Robert
Laing, Robert
McKinna, Fiona
McLaren, Duncan B
O'Sullivan, Joe M
Parikh, Omi
Peedell, Clive
Protheroe, Andrew
Robinson, Angus J
Srihari, Narayanan
Srinivasan, Rajaguru
Staffurth, John
Sundar, Santhanam
Tolan, Shaun
Tsang, David
Wagstaff, John
Parmar, Mahesh K B
Clinical trials referenced in this document:
Documents that mention this clinical trial
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
https://doi.org/10.1016/s0140-6736(15)01037-5
Documents that mention this clinical trial
Prostate cancer
https://doi.org/10.1016/s0140-6736(14)61947-4
Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).
https://doi.org/10.1200/jco.2023.41.16_suppl.5070
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
https://doi.org/10.1016/s0140-6736(15)01037-5
Nodal Clearance Rate and Long-Term Efficacy of Individualized Sentinel Node–Based Pelvic Intensity Modulated Radiation Therapy for High-Risk Prostate Cancer
https://doi.org/10.1016/j.ijrobp.2015.10.031
The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC).
https://doi.org/10.1200/jco.2023.41.16_suppl.5073
Current models, challenges and best practices for work conducted between European academic cooperative groups and industry
https://doi.org/10.1136/esmoopen-2019-000628
Approach for reporting master protocol study designs on ClinicalTrials.gov: qualitative analysis
https://doi.org/10.1136/bmj-2021-067745
Transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT): Efficacy and safety of combining with androgen receptor pathway inhibitors (ARPIs) in metastatic (M1) prostate cancer—Randomised comparison from the STAMPEDE trial platform.
https://doi.org/10.1200/jco.2025.43.5_suppl.21
Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol
https://doi.org/10.1136/bmjopen-2019-034708
This article is maintained by: Elsevier
Article Title: Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Journal Title: The Lancet
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/S0140-6736(15)01037-5
Content Type: article
Copyright: Copyright © 2016 James et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd.